ClinicalTrials.gg
RecruitingNCT05065372MANATEE-T1DUpdated Jun 13, 2025

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

A Phase 1 interventional study of Metformin Hcl 1000Mg Tab and Aminohippurate Sodium 20 % Injection in Type 1 Diabetes, Diabetic Kidney Disease and Cardiovascular Diseases, sponsored by Kalie Tommerdahl. Recruiting at 2 sites in United States. Open to participants aged 12 Years to 25 Years. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Kalie Tommerdahl · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
12 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing metformin in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. Metformin · Diabetes Mellitus, Type 1.

Planned enrollment
9th of 22
60 · median 43
Started
2022
with 1 other
Phase 1
Only one
of the 22
Registered
21st of 22
by date
Lead sponsor
1 of 22
Kalie Tommerdahl

Among the 22 studies testing metformin in Diabetes Mellitus, Type 1, this one is the 9th largest by planned enrollment, is one of 2 that started in 2022, is the only one in phase 1, and was the 21st registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 22 studies testing metformin in Diabetes Mellitus, Type 1 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 12 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing metformin in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

Diabetic kidney disease and cardiovascular disease remain the leading causes of morbidity and mortality in people with type 1 diabetes and are exacerbated with longer duration of diabetes and time outside goal glycemic range. Yet, type 1 diabetes is a complex disease with pathophysiology that extends beyond beta-cell injury and insulin deficiency to include insulin resistance and renal vascular resistance, factors that accelerate cardiovascular disease risk. We have shown that metformin improved peripheral insulin sensitivity and vascular stiffness in youth with type 1 diabetes on multiple daily insulin injections or standard insulin pumps. However, metformin's effect on kidney and endothelial outcomes, and the effects of type 1 diabetes technologies, with or without metformin, on any cardiovascular or kidney outcome, remains unknown. Automated insulin delivery systems combine an insulin pump, continuous glucose monitor, and control algorithm to modulate background insulin delivery and decrease peripheral insulin exposure while improving time in target range and reducing hypoglycemia. We hypothesize that automated insulin delivery systems, particularly when combined with metformin, may modulate renal vascular resistance and insulin sensitivity, thereby impacting cardiometabolic function. MANATEE-T1D is a randomized, double-blind, placebo-controlled trial of 4 months of metformin 2,000 mg daily in 40 youth aged 12-25 years with type 1 diabetes on automated insulin delivery systems vs. 20 control youth with type 1 diabetes on multiple daily injections plus a continuous glucose monitor or an insulin pump in manual mode plus a continuous glucose monitor which will assess for changes in calculated renal vascular resistance and gold standard measures of whole-body and adipose insulin sensitivity, arterial stiffness, and endothelial function.

03

Conditions studied

  • Type 1 Diabetes
  • Diabetic Kidney Disease
  • Cardiovascular Diseases
  • Endothelial Dysfunction
  • Insulin Sensitivity

Keywords

  • Type 1 diabetes
  • Youth
  • Insulin sensitivity
  • Cardiovascular function
  • Diabetic kidney disease
04

Who can participate

Ages eligible
12 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • T1D and using an automated insulin delivery system or multiple daily insulin injections/manual insulin pump plus continuous glucose monitor for > 6 months
  • Age 12-25 years
  • Use of an automated insulin delivery system or multiple daily insulin injections plus a continuous glucose monitor or an insulin pump in manual mode plus a continuous glucose monitor for > 6 months
  • \< 11%
  • No recent episodes of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar syndrome (HHS) (within 30 days)
  • Pubertal (Tanner stage ≥ 2)
  • Weight > 54 kg and > 5th percentile for age and sex

Exclusion criteria

Exclusion Criteria:

  • Blood pressure > 140/90 mm Hg
  • \< 9 g/dL
  • Estimated \< 60 mL/min/1.73 m2 or serum creatinine > 1.2 mg/dL or history of urinary albumin to creatinine ratio ≥ 300mg/g or history of acute kidney injury
  • Use of anti-diabetic agents except insulin, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB's), diuretics, daily non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin, sulfonamides, procaine, thiazosulfone or probenecid
  • Seafood or iodine allergy
  • Pregnancy or breast feeding for females
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Metformin plus automated insulin delivery system

    Some participants with type 1 diabetes using an automated insulin delivery system will be randomized to receive treatment with metformin and will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in addition to assessments of cardiovascular and endothelial function.

    Drug: Metformin Hcl 1000Mg Tab · Drug: Aminohippurate Sodium 20 % Injection · Drug: Iohexol 300 Mg/mL Injectable Solution

  • Placebo comparator
    Placebo plus automated insulin delivery system

    Some participants with type 1 diabetes using an automated insulin delivery system will be randomized to receive treatment with a placebo pill which is identical in appearance to the metformin pill and will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in addition to assessments of cardiovascular and endothelial function.

    Drug: Aminohippurate Sodium 20 % Injection · Drug: Iohexol 300 Mg/mL Injectable Solution · Drug: Placebo

  • Other
    Multiple daily insulin injections or manual insulin pump plus continuous glucose monitor

    Participants with type 1 diabetes using multiple daily injections or an insulin pump in manual mode plus a continuous glucose monitor will not be randomized to receive medication treatment but will undergo RPF (Aminohippurate Sodium Injections 20%), GFR (Iohexol Inj 300 MG/ML), and insulin sensitivity (hyperinsulinemic-euglycemic clamp) assessments, in addition to assessments of cardiovascular and endothelial function.

    Drug: Aminohippurate Sodium 20 % Injection · Drug: Iohexol 300 Mg/mL Injectable Solution

Interventions

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Agent used to modify insulin sensitivity

    Also known as: Fortamet, Glucophage, Glumetza, Riomet

  • DrugP-Aminohippuric AcidStudies of P-Aminohippuric AcidP-Aminohippuric Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance

    Also known as: Sodium 4-amino hippurate (PAH) injection 20% (2g/10 mL), Para-aminohippurate, Aminohippuric acid

  • DrugIohexol 300 Mg/mL Injectable Solution

    Diagnostic aid/agent used to measure glomerular filtration rate

    Also known as: Omnipaque 300

  • DrugPlacebo

    Identical to Metformin Hcl 1000Mg Tab but without metabolic effects

06

What researchers measure

Primary outcomes

  1. Renal vascular resistance

    Renal plasma flow will be measured by para-aminohippurate clearance and used to calculate renal vascular resistance

    Time frame: 4 months

  2. Glomerular filtration rate

    Measured by iohexol clearance

    Time frame: 4 months

Secondary outcomes

  1. Arterial stiffness

    Measured by SphygmoCor

    Time frame: 4 months

  2. Insulin sensitivity

    Measured by hyperinsulinemic-euglycemic clamp

    Time frame: 4 months

07

Study locations

1 of 2 sites recruiting
  • Children's Hospital Colorado/University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
    Active, not recruiting

    Not enrolling at this site.

  • Seattle Children's Hospital
    Seattle, Washington 98102, United States
    Recruiting
    • Kalie Tommerdahl, MD · Contactktomme@uw.edu · (206) 616-9015
    • Kalie Tommerdahl, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Mar 2027, 56 months after the start.

Of 56 non-industry phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 64. This study's planned 56 months is above that.

Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2021
First posted
Oct 4, 2021
StartActual
Jul 1, 2022
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jul 31, 2027
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05065372
Lead sponsor
Kalie Tommerdahl
Responsible party
Kalie Tommerdahl (Associate Professor of Pediatric Endocrinology, Seattle Children's Hospital) — Sponsor-investigator
First posted
Oct 4, 2021
Start date
Jul 1, 2022
Primary completion
Mar 1, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Jun 13, 2025

Study contacts

Kalie Tommerdahl, MD
Contact
ktomme@uw.edu
(206) 616-9015

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion